Influence of various tubal surgeries to serum antimullerian hormone level and outcome of the subsequent IVF-ET treatment

Gynecological Endocrinology

Volumn 29, Issue 4, 2013, Pages 345-349

  Ni, Lili ^a,b   Sadiq, Saima ^a,b   Mao, Yundong ^a,b   Cui, Yugui ^a,b   Wang, Wei ^a,b   Liu, Jiayin ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

IVF ET; Serum AMH; Simple tubal infertility; Tubal surgery

Indexed keywords

DYDROGESTERONE; ESTRADIOL; FOLLITROPIN; GONA F; HUMAN MENOPAUSAL GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DOWN REGULATION; EMBRYO; EMBRYO TRANSFER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FETUS ECHOGRAPHY; FETUS HEART RATE; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYDROSALPINX; HYSTEROSALPINGOGRAPHY; LIVE BIRTH; LUTEAL PHASE; MATERNAL AGE; MENSTRUAL CYCLE; MENSTRUATION; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARIAN RESERVE; OVIDUCT; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALPINGECTOMY; SALPINGITIS; UTERINE TUBE OCCLUSION; BLOOD; NIDATION; OVARY; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; TREATMENT OUTCOME; UTERINE TUBE; UTERINE TUBE DISEASE;

ADULT; ANTI-MULLERIAN HORMONE; EMBRYO IMPLANTATION; FALLOPIAN TUBE DISEASES; FALLOPIAN TUBES; FEMALE; FERTILIZATION IN VITRO; HUMANS; INFERTILITY, FEMALE; OVARY; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; SALPINGECTOMY; TREATMENT OUTCOME;

EID: 84880850948     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.743004     Document Type: Article

References (29)

1. Coughlan C, Li TC. Surgical management of tubal disease and infertility. Obstet Gynaecol Reprod Med 2009;19:4.
2. National Institute for Clinical Excellence (NICE). Guideline 11. Fertility: assessment and treatment for people with fertility problems. Clinical Guideline. London: RCOG Press; 2004.
3. Gelbaya TA, Nardo LG, Fitzgerald CT, et al. Ovarian response to gonadotropins after laparoscopic salpingectomy or the division of fallopian tubes for hydrosalpinges. Fertil Steril 2006; 85:1464-8.
4. Orvieto R, Saar-Ryss B, Morgante G, et al. Does salpingectomy affect the ipsilateral ovarian response to gonadotropin during in vitro fertilization-embryo transfer cycles? Fertil Steril 2011;95:1842-4.
5. Tiras B, Noyan V, Ozdemir H, et al. The changes in ovarian hormone levels and ovarian artery blood flow rate after laparoscopic tubal sterilization. Eur J Obstet Gynecol Reprod Biol 2001;99: 219-21.
6. Hakverdi AU, Taner CE, Erden AC, et al. Changes in ovarian function after tubal sterilization. Adv Contracep 1994;10:51-6.
7. Rojansky N, Halbreich U. Prevalence and severity of premenstrual changes after tubal sterilization. J Reprod Med 1991;36:551-5.
8. Kelekci S, Yorgancioglu Z, Yilmaz B, et al. Effect of tubal ligation on ovarian reserve and the ovarian stromal blood supply. Aust NZ J Obstet Gynaecol 2004;44:449-51.
9. Vigier B, Picard JY, Tran D, et al. Production of antimullerian hormone: another homology between sertoli and granulose cells. Endocrinology 1984;114:1315-20.
10. Kevenaar ME, Meerasahib MF, Kramer P, et al. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 2006;47:3228-34.
11. Fanchin R, Schonauer LM, Righini C, et al. Serum anti mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323-7.
12. Mcllveen M, Skull JD, Ledger WL. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod 2007;22:778-85.
13. De Vet A, Laven JS, de Jong FH, et al. Anti-mullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002;77:357-62.
14. Van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065-71.
15. Fanchin R, Taieb J, Mendez Lozano DH, et al. High reproducibility of serum antimullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005;20:923-7.
16. La Marca A, Stabile G, Carducci Artenisio A, et al. Serum anti-mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006; 21:3103-7.
17. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
18. Practice Committee of American Society for Reproductive Medicine. The role of tubal reconstructive surgery in the era of assisted reproductive technologies. Fertil Steril 2008;90: S250-3.
19. Donaghay M, Lessey BA. Uterine receptivity: alterations associated with benign gynecological disease. Semin Reprod Med 2007;25: 461-75.
20. Tremellen KP, Kolo M, Gilmore A, et al. Anti-mullerian hormone as a marker of ovarian reserve. Aust NZ J Obstet Gynaecol 2005;45:20-4.
21. Ficicioglu C, Kutlu T, Baglam E, et al. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 2006;85: 592-6.
22. Hazout A, Bouchard P, Seifer DB, et al. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 2004;82:1323-9.
23. Lekamge DN, Barry M, Kolo M, et al. Anti-mullerian hormone as a predictor of IVF outcome. Reprod Biomed Online 2007;14: 602-10.
24. Strandell A. The influence of hydrosalpinx on IVF and embryo transfer: a review. Hum Reprod Update 2000;6:387-95.
25. Copperman AB, Wells V, Luna M, et al. Presence of hydrosalpinx correlated to endometrial inflammatory response in vivo. Fertil Steril 2006; 86:972-6.
26. Seli E, Kayisli UA, Cakmak H, et al. Removal of hydrosalpinges increases endometrial leukaemia inhibitory factor (LIF) expression at the time of the implantation window. Hum Reprod 2005;20: 3012-17.
27. Bildirici I, Bukulmez O, Ensari A, et al. A prospective evaluation of the effect of salpingectomy on endometrial receptivity in cases of women with communicating hydrosalpinges. Hum Reprod 2001;16:2422-6.
28. Daftary GS, Kayisli U, Seli E, et al. Salpingectomy increases peri-implantation endometrial HOXA10 expression in women with hydrosalpinx. Fertil Steril 2007;87:367-72.
29. Johnson NP, Mak W, Sowter MC. Laparoscopic salpingectomy for women with hydrosalpinges enhances the success of IVF: a Cochrane review. Hum Reprod 2002;17:543-8.